Oegstgeest, 27 April 2022 – ISA is pleased to announce that its representatives will be participating and presenting at the following business conferences in May 2022. If you would like to meet with our team at any of these events, please contact us through the conference partnering systems or via firstname.lastname@example.org.
LSX World Leaders Congress
Date: 10-11 May 2022, London, UK
Panel Presentation by: Anton Mat, Director Business Development, ISA Pharmaceuticals
Title: Key Multi-Stakeholder Considerations In Early-Stage Commercial Deal-Making
Date & Time: Tuesday, 10 May 2022, 14.30pm BST
Date: 16-18 May 2022, Milan, Italy
Presentation by: Gerben Moolhuizen, Chief Executive Officer, ISA Pharmaceuticals
AMPLIVANT® adjuvant technology has the potential to increase vaccine immune response 10 – 100 foldModi-1 clinical trial to begin in patients with triple negative breast cancer, ovarian cancer, head and neck cancer, and renal cancer
Oegstgeest, The Netherlands, 14 April 2022 – ISA Pharmaceuticals today announces that a clinical trial using ISA’s novel AMPLIVANT® adjuvant technology has started. The trial, run by partner Scancell Holdings plc (AIM: SCLP, “Scancell”) is a multicentre clinical trial, testing the Moditope® vaccine Modi1. This first-in-human clinical trial brings Modi-1 to patients with triple negative breast cancer, ovarian cancer, head and neck cancer, and renal
Data published in the Journal of ImmunoTherapy of Cancer confirms efficacy of combination treatment (ISA101b + anti-PD1)Deep and durable responses have a profound positive effect on patient prognosis with patients disease-free for more than 44 monthsImproved tumour infiltration by immune cells predicted response to therapy
Oegstgeest, March 1, 2022 – ISA today announces the publication of extension data from a key study using lead product ISA101b in the Journal of ImmunoTherapy of Cancer. The study, ISA101 and nivolumab for HPV-16+ cancer: updated clinical efficacy and immune correlates of response, is performed by Guimaraes Sousa, Michael Curran, Bonnie Glisson et al. in
Oegstgeest, the Netherlands, February 17, 2022 – ISA Pharmaceuticals will be attending the following in person scientific and business conferences from February through to April 2022 (subject to travel restrictions), in addition to virtual conferences.
Date: 10 March 2022, Amsterdam
American Association for Cancer Research (AACR) annual meeting
Date: 8-13 April 2022, New Orleans
2nd Chronic HBV drug development
Date: 25-27 April 2022, Boston
If you would like to meet with the ISA Pharmaceutical team at any of the above events, please contact us!